COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00023699
Recruitment Status : Completed
First Posted : October 15, 2003
Last Update Posted : June 24, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer.

PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Primary Peritoneal Cavity Cancer Drug: gefitinib Phase 2

Detailed Description:


  • Determine the antitumor cytostatic activity of gefitinib, in terms of 6-month progression-free survival, in patients with persistent or recurrent ovarian epithelial or primary peritoneal carcinoma.
  • Determine the nature and degree of toxicity in patients treated with this drug.
  • Determine the partial and complete response rates in patients treated with this drug.
  • Determine the duration of progression-free and overall survival in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within 1-2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Study Start Date : August 2001
Actual Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Gefitinib

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

    • Recurrent or persistent disease
  • Must have had prior therapy with no more than 1 platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or other organoplatinum compound) for primary disease
  • Platinum-resistant or refractory

    • Treatment-free interval of less than 6 months after therapy with platinum-containing regimen OR
    • Progression during platinum-containing regimen OR
    • Platinum sensitive defined as treatment-free interval without disease progression for more than 6 months but less than 12 months after therapy with platinum-containing regimen
  • At least 1 lesion measurable in at least 1 dimension

    • At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan, or MRI) OR
    • At least 10 mm by spiral CT scan
  • At least 1 target lesion outside a previously irradiated field
  • Disease must be accessible to core needle biopsy
  • Ineligible for higher priority GOG protocol



  • Not specified

Performance status:

  • GOG 0-2

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN


  • Creatinine no greater than 1.5 times ULN


  • No unstable cardiac disease
  • No myocardial infarction within the past 6 months
  • Coronary artery disease, congestive heart failure, and dysrhythmia allowed if on stable regimen for at least 3 months


  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No sensory or motor neuropathy greater than grade 1
  • No active corneal disease (e.g., keratoconjunctivitis)
  • No active infection requiring antibiotics
  • No evidence of bowel dysfunction that could be related to early bowel obstruction
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer


Biologic therapy:

  • At least 3 weeks since prior immunological agents for the malignancy
  • No concurrent anti-cancer immunotherapy


  • See Disease Characteristics
  • No more than 1 additional prior cytotoxic chemotherapy regimen for recurrent or persistent disease
  • No prior noncytotoxic chemotherapy for recurrent or persistent disease
  • At least 3 weeks since prior chemotherapy for the malignancy and recovered
  • No concurrent anti-cancer chemotherapy

Endocrine therapy:

  • At least 1 week since prior anticancer hormonal therapy
  • Concurrent hormone replacement therapy allowed
  • No concurrent anti-cancer hormonal therapy


  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy for the malignancy and recovered
  • No prior radiotherapy to more than 25% of marrow-bearing areas
  • No concurrent anti-cancer radiotherapy


  • At least 4 weeks since prior surgery (except minor procedures under local anesthesia (e.g., central venous port placement)) and recovered


  • At least 3 weeks since other prior therapy for the malignancy
  • No prior gefitinib
  • No other prior epidermal growth factor receptor inhibitors
  • No prior anticancer therapy that would preclude study therapy
  • No concurrent chlorpromazine
  • No other concurrent investigational agents
  • No other concurrent antineoplastic agents
  • No concurrent CYP3A4-inducing agents, including phenytoin, carbamazepine, barbiturates, nafcillin, rifampicin, or St. John's Wort

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00023699

Show Show 53 study locations
Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Russell J. Schilder, MD Fox Chase Cancer Center
Publications of Results:
Layout table for additonal information Identifier: NCT00023699    
Other Study ID Numbers: CDR0000068852
First Posted: October 15, 2003    Key Record Dates
Last Update Posted: June 24, 2013
Last Verified: August 2003
Keywords provided by National Cancer Institute (NCI):
recurrent ovarian epithelial cancer
primary peritoneal cavity cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action